证券日报网讯 1月9日，长春高新在互动平台回答投资者提问时表示，截至公司招股说明书最后实际可 行日期（2025年9月下旬），公司拥有逾40种处于临床阶段或已提交新药临床试验（IND）申请的候选 药物，其中包括14种处于Ⅲ期临床或新药上市申请（NDA）阶段的候选药物及15种1类创新药，具体情 况可参见公司港股招股书相关内容；截至2025年年底的准确可披露信息情况请关注公司后续年度报告中 的相关内容，同时最近一个季度内公司重点创新产品的相关临床进展可参见前期已披露的相关公告。 （文章来源：证券日报） ...

于本公告日期，Water Lily：持有合共1.58亿股股份，占已发行股份总数约18.71%;及根据股权激励安排 授予其的受限制股份单位，有权收取6315.65万股股份，惟须遵守该等受限制股份单位的相关条件。 拨康视云-B(02592)发布公告，于2025年12月29日，本公司已收到单一最大股东之一Water Lily Consultants Inc.出具的自愿承诺函件，Water Lily已自愿向本公司承诺，将就本公司股份或其他证券(或 于其中拥有法定或实益权益)延长禁售承诺，延长期限自原禁售期届满的翌日(即2026年1月3日)(包括当 日)起至上述日期起6个月届满之日止(即2026年7月2日)，或本公司与Water Lily另行协定的较早日期止。 自愿承诺仅由Water Lily向本公司作出，并不构成Water Lily对任何其他人(包括承诺函及/或香港包销协 议的任何其他方)的任何义务。 董事会认为，Water Lily上述自愿延长禁售期表明，Water Lily对本公司的未来前景充满信心，并认可本 集团业务的积极发展，包括但不限于本集团候选药物在临床开发和商业化方面取得的重大进展。 ...

Core Viewpoint - Baijia Pharmaceutical-B (02659.HK) has announced the launch of its IPO in Hong Kong, with shares expected to be listed on December 10 [1] Group 1: IPO Details - The company plans to issue a total of 37.9117 million shares, with 10% allocated for the Hong Kong offering and 90% for international offering [1] - The maximum offer price is set at HKD 26.38 per share [1] Group 2: Fund Utilization - The funds raised from the IPO will primarily be used for the research and commercialization of core products, as well as advancing existing pipelines and regulatory filings [1] - A portion of the funds will also be allocated to optimizing the synthetic biology technology platform and developing new drug candidates, aiming to strengthen the company's competitive position in four strategic therapeutic areas [1]

"候选药物正在进行二期临床试验，在结肠癌等恶性肿瘤中疗效优于现有临床药物，且毒性更低， 达到预期目标。"11月13日，广西民族大学化学化工学院教授关一富在团队项目进展报告会上向师生们 分享喜讯。 "路虽远，行则将至。"唐平秋表示，下一步，广西民族大学将持续深化改革、深化与东盟的产学研 协同创新和人才双向培养，加强与国家级成果转化平台合作，提升服务专业性与精准性，争取在"十五 五"期间产出更多成果。（顾醒航 付玮烨） 长期以来，众多高校和科研院所存在职务科技成果"不好转""不敢转""不愿转"等难题。《广西科技 创新"十四五"规划》提出，推动高校和科研院所建立健全科技成果转移转化管理与激励制度；2024年， 广西出台职务科技成果转化管理改革试点实施方案，探索建立"赋权+转让+约定收益"成果转化模式， 并明确：在没有牟取非法利益的前提下，对于试点单位在职务科技成果单列管理后的决策失误责任，可 以依规依纪依法免于追究。 顾虑少了，创新活力自然上来了。据不完全统计，广西大学、广西师范大学等8家试点单位累计实 施成果转化1400多项，转化合同总金额超2亿元。广西大学创新横向科研结余经费运作机制，按"同股同 价"收购单位所 ...

Core Viewpoint - Changchun High-tech (000661) is focusing on enhancing its core competitiveness by concentrating on traditional strengths in endocrine metabolism and women's health, as well as innovative directions related to oncology, respiratory, and immune systems [1] Product Development - The company is steadily advancing the research and development of products with differentiation and global market potential, currently having over 40 candidate drugs in clinical stages or for which new drug clinical trial applications (IND) have been submitted [1]

Core Viewpoint - The company is facing scrutiny regarding its high R&D expenses compared to its limited output, raising questions about potential misallocation of resources and the effectiveness of its research strategy [1] Group 1: R&D Investment - The company's R&D expenses are reported to be over three times that of Sanofi, yet the results from these investments are less than one percent of Sanofi's [1] - The company is focusing on enhancing its core competitiveness by concentrating on traditional areas such as endocrine metabolism and women's health, as well as innovative directions related to oncology, respiratory, and immunology [1] Group 2: Product Development - The company is actively advancing its product development pipeline, with over 40 candidates currently in clinical stages or having submitted Investigational New Drug (IND) applications [1]

长春高新在投资者互动平台回答称，为持续提升公司核心竞争力，公司聚焦内分泌代谢、女性健康等传 统优势领域与肿瘤、呼吸、免疫相关创新方向，并稳步推进有差异化和全球市场潜力的产品研发相关工 作，目前有逾40种处于临床阶段或已提交新药临床试验申请（IND）的候选药物。 ...

Core Viewpoint - The Hong Kong stock market experienced a significant decline, with the Hang Seng Index dropping over 4%, reaching a new low in over a month. In contrast, Xuan Bamboo Biotech (2575.HK), spun off from Sihuan Pharmaceutical, saw its stock price surge by 17.1% to HKD 33.96, marking a new high since its IPO [1]. Company Overview - Xuan Bamboo Biotech is an innovative Chinese biopharmaceutical company focused on improving patient health and life through a deep understanding of the Chinese pharmaceutical industry and its unique clinical needs [1]. - Since its acquisition by Sihuan Pharmaceutical in 2008, Xuan Bamboo has established a comprehensive internal R&D platform that supports the development of a diverse and balanced pipeline of drug candidates [1]. Financial Performance - The stock price of Xuan Bamboo Biotech has increased by 192.76% from its IPO price of HKD 11.6, just three trading days after its debut on the Hong Kong Stock Exchange [1]. Drug Development Pipeline - Xuan Bamboo Biotech currently has over ten drug assets actively in development, targeting diseases such as digestive system disorders, tumors, and non-alcoholic fatty liver disease (NASH) [1]. - The company has three assets approved for New Drug Application (NDA), one project in the NDA registration stage, one in Phase III clinical trials, four in Phase I clinical trials, and five that have received Investigational New Drug (IND) approval [1].

Group 1: China Biopharmaceutical (1177 HK) - The company announced a proposed acquisition of 95.09% of Lixin Pharmaceutical for a transaction price of up to $951 million, with a net payment of approximately $501 million after accounting for Lixin's estimated cash and bank deposits of $450 million on the closing date [1][2] - The acquisition will integrate Lixin's four differentiated technology platforms and eight clinical-stage drug candidates, including PD-1/VEGF bispecific antibody and GPRC5D ADC, which have licensing agreements with Merck and AstraZeneca totaling $4 billion [2] - The target price has been raised to HKD 8.00 based on the acquisition and cost reduction efforts, reflecting a potential upside of 17.3% [1][2] Group 2: Flat Glass (6865 HK) - The company expects a significant quarter-on-quarter increase in earnings for 1H25, with a projected profit of RMB 230-280 million, and a midpoint increase of 41% for 2Q25 [3] - The photovoltaic glass industry has seen substantial production cuts since June, with inventory accumulation slowing down, and prices are expected to bottom out and recover starting in August [3] - The target price has been slightly adjusted to HKD 11.45 due to the weaker-than-expected price trends, maintaining a buy rating [3] Group 3: Securities Industry - The securities industry is experiencing strong growth in earnings, with a projected year-on-year increase of 65%-80% for the first half of 2025, averaging a growth of 72% [6][7] - The brokerage business is expected to rebound significantly due to a low base from the previous year, with self-investment income being a major driver of profit growth [6] - The sector's valuation remains attractive, with the A-share securities industry index trading at a price-to-book ratio of 1.38, indicating potential for further valuation increases supported by strong earnings growth [6]